reference/10141036

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10141036

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	986
issn	1470-2045
issueIdentifier	7
pageRange	975-986
publicationName	The Lancet. Oncology
startingPage	975
bibliographicCitation	Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):975–86. doi: 10.1016/s1470-2045(18)30365-6. PMID: 29880291.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ede9023725c15baf9381a2315f910347 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ea3fd6f9bb4dff4196cb14cf447b43b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a25360c98f8ad504ef3b481de98d4a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_13775e94c286feee6382027c5b78d0be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dcd534b82e35fd9a239ac1ed1053451a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b077153dc82e2d9b19db00db18569d4e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a46e4c460fe1e2890b0d4c5fa2fa1f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7408d0a6411bac6c2900118c1f776d1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a88f1eabe1041a5ce4fb4cbc72ed92b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45c852380f911925abf3a064047379b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8875-6747 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b3f1cf46fe37ab153b795f1a9a28e3a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_826403891360b97aa7a56df4dd69bc20 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_680bda570a3d060ec307263004df2fc4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24f7002b369fd406fa48dfa287d57882 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c82e9100015727ac938dad36035814ed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db3ca4f2fb044ddb972b1e11ffba2a92
date	201807
identifier	https://pubmed.ncbi.nlm.nih.gov/29880291 https://doi.org/10.1016/s1470-2045%2818%2930365-6
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
discusses	http://id.nlm.nih.gov/mesh/M0016766 http://id.nlm.nih.gov/mesh/M0537510 http://id.nlm.nih.gov/mesh/M0016884 http://id.nlm.nih.gov/mesh/M0237229 http://id.nlm.nih.gov/mesh/M0001114
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D064129Q000401 http://id.nlm.nih.gov/mesh/D000736Q000008 http://id.nlm.nih.gov/mesh/D064129Q000188 http://id.nlm.nih.gov/mesh/D010879Q000008 http://id.nlm.nih.gov/mesh/D010793Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D018570 http://id.nlm.nih.gov/mesh/D016016 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000367 http://id.nlm.nih.gov/mesh/D064129Q000473 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D016896
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7008 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8564 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8937 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7333 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.4.2.30 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132971 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5755 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23725625 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID187051821

Total number of triples: 79.